Dr. Susan Goodin is the Associate Director, Clinical Trials and Investigational Therapeutics, and Director, Division of Pharmaceutical Sciences at The Cancer Institute of New Jersey and a Professor of Medicine in the Division of Medical Oncology at the UMDNJ Robert Wood Johnson Medical School in New Brunswick. After earning her doctorate in pharmacy from the University of Kentucky College of Pharmacy in Lexington, Dr. Goodin completed a Pharmacy Practice Residency at the University of Kentucky Medical Center in Lexington, and an Oncology Pharmacy Residency at the Lucille P. Markey Cancer Center in conjunction with the University of Kentucky Medical Center. She is a Board Certified Oncology Pharmacist and was elected a Fellow of the American College of Clinical Pharmacy in October 2006. Her research focus is on the development of new drugs for the treatment and prevention of cancer and is the clinical program leader for the Carcinogenesis and Chemoprevention Program at The Cancer Institute of New Jersey. Her other areas of research are in pharmacy practice as well as the treatment of prostate cancer.

Currently, Dr. Goodin serves on the Board of Pharmaceutical Specialties, after serving on the Oncology Specialty Council for the last five years. She is an active member of several professional societies, including the American Society of Health-System Pharmacists, where she is a past-chair for the Section of Clinical Specialists and Scientists, and recently served on the Science Task Force and the Practice Model Advisory Committee.